Literature DB >> 14571821

Outcome of patients with inconsistent results from 13C-urea breath test and bacterial culture at the time of assessment of Helicobacter pylori eradication therapy in Japan.

Yasuhiro Nagahara1, Motowo Mizuno, Toshirou Maga, Kuniharu Ishiki, Tetsuji Okuno, Tomowo Yoshida, Kenji Yokota, Keiji Oguma, Hiroyuki Okada, Takao Tsuji.   

Abstract

BACKGROUND/AIMS: At the assessment of eradication therapy of Helicobacter pylori, the results of 13C-urea breath test and other methods such as bacterial culture are occasionally inconsistent. In this study, we examined the outcomes of inconsistent results.
METHODOLOGY: Four hundred and four patients with peptic ulcer who were H. pylori-positive and who had completed eradication therapy were studied. Bacterial culture, rapid urease tests and 13C-urea breath test were performed between one and three months after the end of the therapy. The cut-off value for the 13C-urea breath test used originally in this study was 2.5 per mil. We investigated the outcome of inconsistent results by following up the patients every 6 to 12 months.
RESULTS: At the initial assessment of eradication therapy, we observed inconsistent results with bacterial culture and 13C-urea breath test in 43 of 404 patients. Most of them (40 of 43) were culture-negative but urea breath test-positive, and the majority became negative for both tests. Based on the follow-up results, the optimum value for 13C-urea breath test at the assessment of eradication therapy was found to be 3.5 per mil.
CONCLUSIONS: We found that outcomes of inconsistent results were variable, indicating the importance of the follow-up of patients after eradication therapy of H. pylori.

Entities:  

Mesh:

Year:  2003        PMID: 14571821

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study.

Authors:  Susumu Take; Motowo Mizuno; Kuniharu Ishiki; Fumihiro Hamada; Tomowo Yoshida; Kenji Yokota; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2014-10-29       Impact factor: 7.527

2.  The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori.

Authors:  Susumu Take; Motowo Mizuno; Kuniharu Ishiki; Tomowo Yoshida; Nobuya Ohara; Kenji Yokota; Keiji Oguma; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2010-11-20       Impact factor: 7.527

3.  Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases.

Authors:  Susumu Take; Motowo Mizuno; Kuniharu Ishiki; Yasuhiro Nagahara; Tomowo Yoshida; Kenji Yokota; Keiji Oguma
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

4.  Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan.

Authors:  Susumu Take; Motowo Mizuno; Kuniharu Ishiki; Takayuki Imada; Tetsuji Okuno; Tomowo Yoshida; Kenji Yokota; Keiji Oguma; Masahide Kita; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2012-02-17       Impact factor: 7.527

Review 5.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15

6.  Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication.

Authors:  Susumu Take; Motowo Mizuno; Kuniharu Ishiki; Chiaki Kusumoto; Takayuki Imada; Fumihiro Hamada; Tomowo Yoshida; Kenji Yokota; Toshiharu Mitsuhashi; Hiroyuki Okada
Journal:  J Gastroenterol       Date:  2019-10-30       Impact factor: 7.527

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.